Corteva (NYSE:CTVA) Upgraded to “Strong-Buy” at Zacks Research

Corteva (NYSE:CTVA) was upgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued on Monday,Zacks.com reports.

CTVA has been the topic of a number of other reports. Royal Bank Of Canada lifted their target price on shares of Corteva from $95.00 to $97.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. Barclays raised their price target on shares of Corteva from $84.00 to $91.00 and gave the stock an “overweight” rating in a report on Thursday, June 11th. Citigroup lifted their price target on shares of Corteva from $83.00 to $85.00 and gave the company a “neutral” rating in a research report on Thursday, May 7th. Rothschild & Co Redburn upped their price objective on Corteva from $80.00 to $90.00 and gave the company a “neutral” rating in a report on Wednesday, April 29th. Finally, Jefferies Financial Group increased their price objective on Corteva from $95.00 to $97.00 in a research report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $88.95.

Corteva Stock Down 1.3%

Shares of NYSE:CTVA opened at $84.91 on Monday. Corteva has a 52-week low of $60.53 and a 52-week high of $87.69. The stock has a market cap of $56.79 billion, a P/E ratio of 49.95, a PEG ratio of 2.63 and a beta of 0.56. The business has a fifty day moving average of $80.53 and a two-hundred day moving average of $77.87. The company has a quick ratio of 1.03, a current ratio of 1.47 and a debt-to-equity ratio of 0.07.

Corteva (NYSE:CTVA) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $1.50 EPS for the quarter, topping the consensus estimate of $1.18 by $0.32. Corteva had a return on equity of 9.95% and a net margin of 6.50%.The business had revenue of $4.91 billion for the quarter, compared to analyst estimates of $4.64 billion. During the same quarter in the previous year, the firm earned $1.13 EPS. The company’s quarterly revenue was up 11.0% compared to the same quarter last year. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. On average, research analysts expect that Corteva will post 3.72 earnings per share for the current year.

Hedge Funds Weigh In On Corteva

Several hedge funds have recently bought and sold shares of the company. Drummond Knight Asset Management Pty Ltd acquired a new stake in shares of Corteva during the fourth quarter worth about $25,713,000. Avior Wealth Management LLC grew its holdings in shares of Corteva by 464.7% in the fourth quarter. Avior Wealth Management LLC now owns 32,901 shares of the company’s stock valued at $2,205,000 after purchasing an additional 27,075 shares in the last quarter. Arbejdsmarkedets Tillaegspension acquired a new position in shares of Corteva in the fourth quarter valued at approximately $23,679,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Corteva by 23.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 110,075 shares of the company’s stock worth $7,378,000 after buying an additional 20,957 shares during the period. Finally, Leonteq Securities AG acquired a new stake in Corteva during the 4th quarter worth approximately $2,350,000. Institutional investors and hedge funds own 81.54% of the company’s stock.

Corteva Company Profile

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.